[Skip to content]

Print this page
.

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120121-140; 141-160; 161-180; 181-200201-220221-240241-260261-280; 281+

NICE TAs 221-240

 

REF

 

TITLE

 

DHFT Formulary link

East Midlands Cancer Network link (cancer drugs only)

TA221

Thrombocytopenic purpura - romiplostim (TA221)

9.1.2 - 9.1.6 Megaloblastic, hypoplastic, haemolytic and renal anaemias: 9.1.4 Drugs used in autoimmune thrombocytopenic purpura

 

TA222

Ovarian cancer (relapsed) - trabectedin (TA222)

Not supported

Not supported

TA223

Peripheral arterial disease - cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate (TA223)

2.6 Nitrates and calcium-channel blockers: 2.6.4 Peripheral and cerebral vasodilators

 

TA224

Rheumatoid arthritis (methotrexate-naïve) - golimumab (terminated appraisal) (TA224)  

Withdrawn

 

TA225

Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab (TA225)

Replaced by NICE TA 375

 

TA226

Lymphoma (follicular non-Hodgkin's) - rituximab (TA226)

10.1.2 - 10.1.4 Corticosteroids, rheumatic disease suppressants, gout: 10.1.3 Drugs which suppress the rheumatic disease process

 

TA227

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) (TA227)

 

Not supported

TA228

Multiple myeloma (first line) - bortezomib and thalidomide (TA228)

8.2 Drugs affecting the immune response: 8.2.4 Other Immunomodulating Drugs

EMCN algorithm

DHFT protocol 

TA229

Macular oedema (retinal vein occlusion) - dexamethasone (TA229)  

11.4 Corticosteroirds and other anti-inflammatory preparations: 11.4.1 Corticosteroids

 

TA230

Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)

2.8 Anticoagulants: 2.8.1 Parenteral anticoagulants

 

TA231

Depression - agomelatine (terminated appraisal) (TA231)  

Withdrawn

 

TA232

Epilepsy (partial) - retigabine (adjuvant) (TA232)

4.8 Antiepileptics  

 

TA233

Ankylosing spondylitis - golimumab (TA233)

10.1.2 - 10.1.4 Corticosteroids, rheumatic disease suppressants, gout: 10.1.3 Drugs which suppress the rheumatic disease process

 

TA234

Rheumatoid arthritis - abatacept (2nd line) (TA234)

No drug implications

 

TA235

Osteosarcoma - mifamurtide (TA235)

 

Not routinely delivered at DHFT

TA236

Acute coronary syndromes - ticagrelor (TA236)

2.9 Antiplatelet drugs

 

TA237

Macular oedema (diabetic) - ranibizumab (TA237)

Replaced by: Macular oedema (diabetic) - ranibizumab (TA274) (April 2013)

No drug implications

 

TA238

Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238)

10.1.2 - 10.1.4 Corticosteroids, rheumatic disease suppressants, gout: 10.1.3 Drugs which suppress the rheumatic disease process

 

TA239

Breast cancer (metastatic) - fulvestrant (TA239)

No drug implications

 

TA240

Colorectal cancer (metastatic) - panitumumab (terminated appraisal) (TA240)

 

Not supported